NeOnc Technologies Holdings, Inc. Common Stock Total Assets
NeOnc Technologies Holdings, Inc. Common Stock total assets. Based on the latest financial reports, NeOnc Technologies Holdings, Inc. Common Stock (NTHI) holds total assets worth $5.23 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of NeOnc Technologies Holdings, Inc. Common for the company's overall valuation and market capitalisation.
Total Assets of NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
Total assets of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025. This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See current stock price of NeOnc Technologies Holdings, Inc. Common for real-time trading data and today's change.
NeOnc Technologies Holdings, Inc. Common Stock - Asset Composition Analysis
NeOnc Technologies Holdings, Inc. Common Stock Total Assets Breakdown (December 2025)
NeOnc Technologies Holdings, Inc. Common Stock total assets breakdown as of December 2025. NeOnc Technologies Holdings, Inc. Common Stock's total assets of $5.23 Million consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 2.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $500.00K | 17.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how NeOnc Technologies Holdings, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NTHI net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NeOnc Technologies Holdings, Inc. Common Stock's current assets represent 49.2% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 77.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 17.7% of total assets.
NeOnc Technologies Holdings, Inc. Common Stock Competitors by Total Assets
Key competitors of NeOnc Technologies Holdings, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
NeOnc Technologies Holdings, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.14 | 0.11 | 0.32 |
| Quick Ratio | 0.14 | 0.11 | 0.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-20.13 Million | $-12.82 Million | $-1.58 Million |
NeOnc Technologies Holdings, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between NeOnc Technologies Holdings, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 25.81 |
| Asset Growth Rate (YoY) | -17.4% |
| Total Assets | $2.82 Million |
| Market Capitalization | $72.88 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NeOnc Technologies Holdings, Inc. Common Stock's assets at a significant premium (25.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NeOnc Technologies Holdings, Inc. Common Stock's assets decreased by 17.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NeOnc Technologies Holdings, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of NeOnc Technologies Holdings, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.82 Million | -17.37% |
| 2024-12-31 | $3.42 Million | +170.06% |
| 2023-12-31 | $1.27 Million | +73.65% |
| 2022-12-31 | $728.68K | +2142.72% |
| 2021-12-31 | $32.49K | -- |
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical… Read more